scholarly journals Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive

Contraception ◽  
2014 ◽  
Vol 89 (4) ◽  
pp. 299-306 ◽  
Author(s):  
David J. Portman ◽  
Andrew M. Kaunitz ◽  
Brandon Howard ◽  
Herman Weiss ◽  
Jennifer Hsieh ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety ◽  
Combined Oral Contraceptive

Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol

Contraception ◽  
2016 ◽  
Vol 93 (3) ◽  
pp. 249-256 ◽  
Author(s):  
Robin Kroll ◽  
Ronald Ackerman ◽  
Robert Feldman ◽  
Brandon Howard ◽  
Herman Weiss ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety ◽  
Combined Oral Contraceptive

Efficacy and Safety of the Combined Oral Contraceptive Ethinylestradiol/Drospirenone (Yasmin®) in Healthy Chinese Women

2010 ◽  
pp. 1
Author(s):  
Fan Guang-Sheng ◽  
Bian Mei-Lu ◽  
Cheng Li-Nan ◽  
Cao Xiao-Ming ◽  
Huang Zi-Rong ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Chinese Women ◽  
Efficacy And Safety ◽  
Combined Oral Contraceptive ◽  
Healthy Chinese

scholarly journals Safety and Efficacy of Levonorgestrel 0.10 mg and Ethinyl Estradiol 0.02 mg plus Ethinyl Estradiol 0.01 mg in an Extended-Cycle Oral Contraceptive Regimen

2010 ◽  
Vol 2 ◽  
pp. CMT.S4661
Author(s):  
Radhika Rible ◽  
Ram Parvataneni ◽  
Angela Chen
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Pivotal Trial ◽  
Combined Oral Contraceptive ◽  
Free Interval ◽  
Effective Option ◽  
Effective Contraception ◽  
Combined Hormonal Contraception ◽  
Extended Cycle

Extended-cycle combined hormonal contraception has become a common practice among women seeking effective contraception and menstrual regulation. Extended cycle regimens have the benefit of decreasing scheduled bleeding as compared to traditional combined oral contraceptive (COC) regimens containing 21 days of hormones followed by a 7-day hormone-free interval (HFI) by reducing the frequency of the HFI. The newest FDA approved product in this family of contraceptive regimens is a 91-day COC regimen containing 0.02 mg ethinyl estradiol (EE) and 0.1 mg levonorgestrel (LNG) for 84 days followed by a 7-day interval with 0.01 mg EE. This regimen has been evaluated in one pivotal trial and demonstrated to have efficacy and a side effect profile similar to the other currently available FDA approved 91-day extended-cycle regimens. This is the first 91-day regimen formulated with 0.02 mg EE and offers women an effective option for contraception and menstrual cycle control.

The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol

Contraception ◽  
2010 ◽  
Vol 81 (1) ◽  
pp. 41-48 ◽  
Author(s):  
Robin Kroll ◽  
Kathleen Z. Reape ◽  
Marya Margolis
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety

Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometrium

2001 ◽  
Vol 76 (1) ◽  
pp. 102-107 ◽  
Author(s):  
Frank Lüdicke ◽  
Elisabeth Johannisson ◽  
Frans M Helmerhorst ◽  
Aldo Campana ◽  
Jean-Michel Foidart ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Human Endometrium ◽  
Combined Oral Contraceptive

Estradiol Valerate/Dienogest: A Novel Oral Contraceptive

2011 ◽  
Vol 45 (10) ◽  
pp. 1256-1261 ◽  
Author(s):  
Karen L Whalen ◽  
Renee Rose
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Data Extraction ◽  
Estradiol Valerate ◽  
Efficacy And Safety ◽  
Data Synthesis ◽  
Efficacy Trials ◽  
Study Selection ◽  
Pearl Index

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the new oral contraceptive estradiol valerate/dienogest. Data Sources: Searches of PubMed (1966-July 2011) and International Pharmaceutical Abstracts (1970-July 2011) were conducted using the key words estradiol valerate, dienogest, Natazia, and Olaira. Bibliographies of retrieved articles were reviewed to identify additional références. Study Selection and Data Extraction: All identified studies published in English and involving efficacy and safety of estradiol valerate/dienogest as an oral contraceptive were reviewed. Data Synthesis: Estradiol valerate/dienogest is a 4-phasic oral contraceptive approved for the prevention of pregnancy. The 4-phasic design allows for acceptable cycle control with this hormonal combination. In efficacy trials of estradiol valerate/dienogest in women aged 18–35 years, the Pearl Index ranged from 0.40 to 1.64, a range comparable to that of other combination oral contraceptives. The safety profile was also similar to that of other oral contraceptives, with headache, metrorrhagia, breast tenderness, nausea or vomiting, acne, and weight gain reported as the most common adverse effects. Menstrual bleeding patterns and cycle control with estradiol valerate/dienogest were comparable to those of a monophasic oral contraceptive containing ethinyl estradiol/levonorgestrel. Estradiol valerate/dienogest differs from other oral contraceptives in that il necessitates more stringent dosing guidelines for maximum contraceptive efficacy. New starts should be on the first day of menses only, and a back-up method of contraception is required for the first 9 days, as compared to 7 days with other oral contraceptives. Back-up contraception is usually required for any pill taken more than 12 hours later than scheduled. Conclusions: Estradiol valerate/dienogest is an effective oral contraceptive. Because it has more stringent start times and requires a longer duration of back-up contraception and stricter adherence, estradiol valerate/dienogest should be reserved for patients who are intolerant of other combination oral contraceptives.

Sign in / Sign up

Export Citation Format

Share Document